A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)

Summary

This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST) in subjects with centre-involved diabetic macular oedema (DME).

Timeline

Start

2016-12-22

Primary completion

2018-04

Completion

2018-04

Outcome

Met primary endpoint

release “NCT03071068). The study met its primary endpoint of safety for both the 4 mg and 8 mg doses.” bioinvent.com ↗

Drugs

Indications